A5052403208- Cancer Immunotherapy and Biomarkers
- Diabetes Management and Research
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Pancreatic function and diabetes
- Diabetes Treatment and Management
- Melanoma and MAPK Pathways
- Diabetes and associated disorders
- Diet and metabolism studies
- Ovarian cancer diagnosis and treatment
- Immune Cell Function and Interaction
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- vaccines and immunoinformatics approaches
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Cancer Diagnosis and Treatment
- Cutaneous Melanoma Detection and Management
- Brain Metastases and Treatment
- Colorectal and Anal Carcinomas
- German Literature and Culture Studies
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Electrolyte and hormonal disorders
- Chronic Lymphocytic Leukemia Research
Olivia Newton-John Cancer Wellness & Research Centre
2016-2024
La Trobe University
2019-2024
Austin Health
2015-2023
Profil Institute for Metabolic Research
2006-2022
Peninsula Health
2020-2022
Cancer Australia
2021
Auckland District Health Board
2021
Princess Alexandra Hospital
2021
BioNTech (Germany)
2020
Ibero American University
2020
A one-two, CAR-T cell punch Chimeric antigen receptor (CAR)–T cells have been clinically effective in killing certain hematological malignancies, but achieving long-term patient responses for solid tumors remains a challenge. Reinhard et al. describe two-part “CARVac” strategy to overcome poor stimulation and vivo. They introduce the tight junction protein claudin 6 (CLDN6) as new target designed nanoparticulate RNA vaccine encoding chimeric directed toward CLDN6. This lipoplex promotes...
BACKGROUND The immunotherapy (IT) agents ipilimumab and interleukin‐2 as well BRAF inhibitors (BRAFi) vemurafenib dabrafenib, with or without trametinib (MEK inhibitors), are all FDA‐approved treatments for metastatic melanoma, but there few studies to guide optimal sequencing. This retrospective analysis describes the outcomes of patients treated either BRAFi before IT BRAFi. METHODS A cohort alone MEK inhibitor was retrospectively identified. Response rate (RR), overall survival (OS),...
<h3>Importance</h3> Biliary tract cancers represent a rare group of malignant conditions with very limited treatment options. Patients advanced disease have poor outcome current therapies. <h3>Objective</h3> To evaluate the efficacy and safety combination immunotherapy nivolumab ipilimumab in patients biliary cancers. <h3>Design, Setting, Participants</h3> The CA209-538 prospective multicenter phase 2 nonrandomized clinical trial included including This subgroup analysis evaluated 39 from...
Abstract Purpose: Combination immunotherapy with anti–CTLA-4 and anti–PD-1 blockade has demonstrated significant clinical activity across several tumor types. Neuroendocrine tumors (NET) are a heterogeneous group of rare limited treatment options. CA209-538 is trial combination ipilimumab nivolumab in cancers, including advanced NETs. Patients Methods: prospective multicenter patients cancers. received at dose 3 mg/kg 1 every three weeks for four doses, followed by two continued up to 96...
Abstract Immune checkpoint blockade (ICB) targeting programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte 4 (CTLA-4) can induce remarkable, yet unpredictable, responses across a variety of cancers. Studies suggest that there is relationship between cancer patient’s gut microbiota composition clinical response to ICB; however, defining microbiome-based biomarkers generalize cohorts has been challenging. This may relate previous efforts quantifying species (or higher taxonomic...
Aim: This study compared the time‐action profiles of novel albumin‐bound basal insulin analogue NN344 with those detemir and glargine in individuals type 2 diabetes. Methods: Twenty‐seven insulin‐treated men diabetes [body mass index 30.8 ± 2.6 kg/m (mean s.d.), haemoglobin A 1c 7.6 1.1%] were enrolled this randomized, double‐blind trial participated six euglycaemic glucose clamp experiments [target blood (BG) 5 mmol/l] each. Participants received three at a dose 0.8, 1.6 2.8 dosing units...
Recent phase III clinical trials have established the superiority of anti-PD-1 antibodies pembrolizumab and nivolumab over anti-CTLA-4 antibody ipilimumab in first-line treatment patients with advanced melanoma. Ipilimumab will be considered for second-line after failure therapy. We retrospectively identified a cohort 40 metastatic melanoma who received single-agent therapy or were treated on progression at dose 3 mg kg−1 maximum four doses. Ten percent achieved an objective response to...
There is limited data on the efficacy of anti-programmed death 1 (PD-1) antibodies in patients (pts) with melanoma brain metastasis (BM), particularly those which are symptomatic. We retrospectively assessed pts BM treated PD-1 antibodies, nivolumab and pembrolizumab. Clinicopathologic treatment parameters were collected outcomes determined for intracranial (IC) response rate (RR) using a modified RECIST criteria, up to five IC target lesions used determine response, disease control (DCR)...
To compare steady state pharmacodynamic and pharmacokinetic profiles of insulin glargine 300U/mL (Gla-300) with degludec 100U/mL (Deg-100) in people type 1 diabetes.This single-centre, randomized, double-blind crossover euglycaemic clamp study included two parallel cohorts fixed once-daily morning dose regimens. For both insulins participants received 0.4 (n=24) or 0.6U/kg/day (n=24), before breakfast, for 8 days prior to the clamp. The main endpoint was within-day variability (fluctuation)...
Abstract Aim To assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of basal insulin Fc (BIF; LY3209590), a fusion protein combining novel single‐chain variant together with human IgG2 domain, following single multiple once‐weekly BIF administration. Materials Methods The ascending dose, 15‐day study assessed four doses (5‐35 mg) in healthy participants people type 2 diabetes (T2D). In 6‐week dose study, T2D, previously treated insulin, received glargine daily or...
Abstract Mitragynine (MG) is an indole alkaloid of the Thai medicinal plant Mitragyna speciosa (Kratom in Thai) and reported to have opioid agonistic properties. Because its stimulant euphoric effects, Kratom used as a herbal drug abuse. The aim presented study identify phase I II metabolites MG rat human urine after solid‐phase extraction (SPE) using liquid chromatography‐linear ion trap mass spectrometry providing detailed structure information MS n mode particularly with high resolution....
Ipilimumab is a monoclonal antibody that blocks the immune-inhibitory interaction between CTL antigen 4 (CTLA-4) and its ligands on T cells. Clinical trials in cancer patients with ipilimumab have shown promising antitumor activity, particularly advanced melanoma. Often, tumor regressions these are correlated immune-related side effects such as dermatitis, enterocolitis, hypophysitis. Although reactions believed to be immune-mediated, antigenic targets for cellular or humoral immune response...
Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of long-acting and short-acting insulin analogs. The primary objective this study was to investigate the pharmacodynamic response once-daily IDegAsp dosing in patients with type 1 diabetes. Pharmacokinetic response, as well safety tolerability, were assessed secondary objectives. This single-center, open-label, single-arm study. Twenty-two subjects received degludec (IDeg) (0.42 U/kg) for five consecutive days [with...
BACKGROUND The v‐raf murine sarcoma viral oncogene homolog B (BRAF) inhibitor (BRAFi) drugs dabrafenib and vemurafenib have high response rates in BRAF ‐mutant, metastatic melanoma; however, 50% of patients progress by 7 months. In this study, the authors examined nature management disease progression (PD) on BRAFi treatment, including characteristics outcomes who received continued treatment beyond (TBP). METHODS Clinicopathologic data at baseline time PD were collected for all with ‐mutant...
Acral melanoma is a rare subtype with poor prognosis. Importantly, these patients were not identified as specific subgroup in the landmark trials involving ipilimumab and anti-programmed cell death protein-1 (PD-1) agents nivolumab pembrolizumab. There therefore an absence of prospective clinical trial evidence regarding efficacy checkpoint inhibitors (CPIs) this population. has lower tumor mutation burden (TMB) than other cutaneous sites, primary site associated differences TMB. However...
CD 4 + 25 F ox P 3 naturally occurring regulatory T ( reg) cells play a crucial role in the maintenance of immune tolerance and preventing autoimmune pathology. Interventions that expand reg are highly desirable, as they may offer novel treatment options variety transplantation settings. Paralleling previous preclinical studies, we demonstrate here administration hematopoietic growth factor lt3 L to human subjects increases frequency absolute number cells, reduces ratio 8 peripheral blood....
Background: There are no widely accepted parameters to assess the quality of glucose clamps. Thus, we selected different describing clamp quality. These were then evaluated in clamps carried out with ClampArt, a novel CE-marked, state-of-the-art fully automated device employing continuous blood (BG) measurements and minute-by-minute adaptations infusion rate (GIR). Methods: Thirty-nine performed 10 healthy 29 subjects type 1 diabetes (T1DM) (total duration 583 h). ClampArt-based BG compared...